XL184 (cabozantinib) for medullary thyroid carcinoma

Abstract A13: Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184

(2012) B. Sennino et al.   MOLECULAR CANCER THERAPEUTICS

Novel treatment of medullary thyroid cancer

(2011) Masahiro Sugawara et al.   Current Opinion in Endocrinology Diabetes and Obesity

Targeted therapy of thyroid cancer

(2010) Steven I. Sherman   BIOCHEMICAL PHARMACOLOGY

Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer

(2010) Elaine T. Lam et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

(2010) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC

(2010) Karin Frank-Raue et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

(2009) Martin J. Schlumberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

(2009) Richard T. Kloos (Chair) et al.   THYROID

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE